

DAFTAR PUSTAKA

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. International Agency for Research on Cancer 2020. *Glob Cancer Obs Cancer Today*. 2020;419:1-2.
2. Richters A, Aben KKH, Kiemeny LALM. The global burden of urinary bladder cancer: an update. *World J Urol*. 2020;38(8):1895-1904.
3. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. Published online 2020:1-18.
4. American Cancer Society. Cancer Facts & Figures 2018. In: ; 2018.
5. Smith B, Milowsky MI. Gender disparities in chemotherapy use and survival in patients with advanced bladder cancer. 2020;122(13):2012-2020.
6. The Global Cancer Observatory. Cancer Incident in Indonesia. *Int Agency Res Cancer*. 2020;858:1-2.
7. Iscan, Hendrizal. Efmansyah DA. Karsinoma buli-buli yang dirawat di bangsal bedah RSUP DR.M.Djamil Padang Tahun 2000-2005. Published online 2006.
8. RSUP. Kejadian Karsinoma Buli-buli 2018. In: Medical Record RSUP Dr.M.Djamil; 2018.
9. Yong ZK, Zheng WQ, Lin N, Lin YWY, Tao X. Risk factors for upper tract urothelial recurrence following local excision of bladder cancer. 2018;(June):1-6.
10. National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management of bladder cancer. *BJU Int*. 2017;120(6):755-765.
11. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. *J Clin Oncol*. 2019;37(18):1547-1557.
12. Zarifmahmoudi L, Ghorbani H, Sadri K, et al. Sentinel Node Biopsy in Urothelial Carcinoma of the Bladder: Systematic Review and Meta-Analysis Urologia. Published online 2019.
13. Rouanne M, Bajorin DF, Hannan R, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. *Eur Urol Oncol*. (2020):1-11.
14. Chou YJ, Kuo HJ, Shun SC. Cancer prehabilitation programs and their effects on quality of life. *Oncol Nurs Forum*. 2018;45(6):726-736.
15. European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 Scoring Manual. 2001;30.
16. Elfarianti B. *FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN TINGKAT KUALITAS HIDUP PENDERITA KANKER PAYUDARA.*; 2019.
17. Bhanvadia SK. Bladder Cancer Survivorship. Published online 2018.
18. Palareti G, Legnani C, Cosmi B, et al. The impact of bladder cancer on health-related quality of life. *Int J Lab Hematol*. 2016;38(1):42-49.
19. W.Rohen, Johannes. Yokochi, Chihiro. Drecoll EL. *Color Atlas of Anatomy A Photographic Study of the Human Body*. 7th ed.; 2011.
20. Hansen JT. *Netter's Clinical Anatomy*. Vol 47. 3rd ed. (Tannian P, ed.).

- Elsevier Inc; 2014.
21. Paulsen F, Waschke J. *Sobotta Atlas Anatomi Manusia: Anatomi Umum Dan Muskuloskeletal*. 15th ed. Elsevier Inc; 2015.
 22. Gartner LP, Hiatt JL. *A Textbook of Histology*. Vol 175. 3rd ed. (Ozals I, Mahon J, eds.). Elsevier Inc; 1961.
 23. Mescher AL. *Jonqueira's Basic Histology*. Vol 511. 13th ed. Mc Graw-Hill; 2013.
 24. Kellogg J, John B. *Handbook of Urology*. 1st ed. Wiley Blackwell; 2014.
 25. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*. 2013;63(2):234-241.
 26. Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. *Cancer*. 2016;122(13):2012-2020.
 27. Yu Z, Yue W, Jiuzhi L, Youtao J, Guofei Z, Wenbin G. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. *Urolithiasis*. Published online 2018;573-579.
 28. Guo CC, Czerniak B. Bladder Cancer in the Genomic Era. 2018;11:4.
 29. Carreón T, Hein MJ, Hanley KW, Viet SM, Ruder AM. Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant. *Occup Environ Med*. 2014;71(3):175-182.
 30. Ma S, Zhang T, Jiang L, et al. Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer. *Cancer Manag Res*. 2019;11:7171-7181.
 31. Supit W, Mochtar CA, Sugiono M, Umbas R. Survival of patients with transitional cell carcinoma of the urinary bladder in indonesia: A single institution review. *Asian Pacific J Cancer Prev*. 2011;12(2):549-553.
 32. Kumar, Cotran, Robbins. *Buku Ajar Patologi*. Vol 2. 7th ed. (Asroruddin M, Hartanto H, Darmaniah N, eds.). EGC; 2007.
 33. Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. *J Natl Cancer Inst*. 2007;99(7):558-568.
 34. Boldini M, Cerantola Y, Valerio M, Jichlinski P. *Urologie*. Vol 11.; 2015.
 35. Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. *Eur Urol*. 2014;65(4):778-792.
 36. Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. *Histopathology*. 2019;74(1):112-134.
 37. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. *Eur Urol*. 2011;59(6):1009-1018.
 38. Umbas R, Hardjowijoto S, Arif C, Safriadi F, Djatisoesanto W, Sihombing AT. *Panduan Penanganan Kanker Kandung Kemih Tipe Urotelial.*; 2014.
 39. Shakespeare W. *Urology A Handbook for Medical Students.*; 2014.
 40. Kim LHC, Patel MI. Transurethral resection of bladder tumour (TURBT). *Transl Androl Urol*. 2021;9(6):3056-3072.
 41. Pietzak EJ, Zabor EC, Bagrodia A, et al. HHS Public Access.

- 2020;75(2):231-239.
42. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. *Nat Rev Urol*. 2018;15(10):615-625.
 43. Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG. *Nat Rev Urol*. 2017;14(4):244-255.
 44. Aluwini S, Rooij PHE Van, Kirkels WJ, Boormans JL, Kolkman-deurloo IK, Wijnmaalen A. Bladder Function Preservation With Brachytherapy , External Beam Radiation Therapy , and Limited Surger in Bladder Cancer Patients : Long-Term Results. *Radiat Oncol Biol*. 2014;88(3):611-617. <http://dx.doi.org/10.1016/j.ijrobp.2013.11.227>
 45. Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. *Cancer*. 2017;123(22):4346-4355.
 46. Prutkin JM, Feinstein AR. Quality-of-life measurements: Origin and pathogenesis. *Yale J Biol Med*. 2002;75(2):79-93.
 47. Post MWM. Definitions of quality of life: What has happened and how to move on. *Top Spinal Cord Inj Rehabil*. 2014;20(3):167-180.
 48. Hagen NA, Addington-Hall J, Sharpe M, Richardson A, Cleeland CS. The Birmingham international workshop on supportive, palliative, and end-of-life care research. *Cancer*. 2006;107(4):874-881.
 49. Sacher RA. *Tinjauan Klinis Hasil Pemeriksaan, Laboratorium*. (Wulandari D, ed.). EGC; 2012.
 50. Sibeoni J, Picard C, Orri M, et al. Patients' quality of life during active cancer treatment: A qualitative study. *BMC Cancer*. 2018;18(1):1-8.
 51. Husson O, Rooij BH, Kieffer J, et al. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry. *Oncologist*. 2020;25(4):1-11.
 52. Mina S, Pardo Munevar CA, Osorio D, García-Perdomo HA. Life quality evaluation in patients with bladder cancer: A systematic review. *Actas Urol Esp*. 2019;43(4):198-204.
 53. Hevér N V., Péntek M, Balló A, et al. Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. *Pathol Oncol Res*. 2015;21(3):619-627.
 54. Kemenkes. Sistem Kesehatan Nasional. Published online 2020.
 55. Bladder C, Be C, Early F, et al. Bladder Cancer Early Detection , Diagnosis , and Staging. *Am Cancer Soc*. Published online 2020:1-24.
 56. Yusuf Y. Panduan Praktek Klinik Kanker Buli RSUD Dr. M. Djamil Padang. Published online 2021.
 57. Effendi ERBB dengan GHKB di RDMDPT 2014-2018. *Hubungan Riwayat Batu Buli-Buli Dengan Gambaran Histopatologi Karsinoma Buli-Buli Di RSUD Dr. M. Djamil Padang Tahun 2014-2018.*; 2018. <http://scholar.unand.ac.id/61716/2/2>. BAB 1 (Pendahuluan).pdf
 58. Ifan. Morbiditas Dan Mortalitas Pasca Sistektomi Radikal Pada Kanker Buli Di Rsud Dr Soetomo Surabaya. *Kesehatan, Univ Airlangga*. Published online 2019.

59. Shi B, Zhang K, Zhang J, Chen J, Zhang N, Xu Z. Relationship Between Patient Age and Superficial Transitional Cell Carcinoma Characteristics. *Urology*. 2008;71(6):1186-1190.
60. Pandu Putra Anugrah, Pandu Ishaq Nandana, Marie Yuni Andari. Insidensi Penyakit Kanker Buli-buli di RSUD Provinsi Nusa Tenggara Barat periode 2017-2018. *Unram Med J*. 2019;8(2):1-4.
61. Janisch F, Shariat SF, Schernhammer E, Rink M, Fajkovic H. The interaction of gender and smoking on bladder cancer risks. *Curr Opin Urol*. 2019;29(3):249-255.
62. Tripathi A, Gupta S. Androgen receptor in bladder cancer: A promising therapeutic target. *Asian J Urol*. 2020;7(3):284-290. <https://doi.org/10.1016/j.ajur.2020.05.011>
63. Osawa T, Wei JT, Abe T, Honda M, Yamada S, Furumido J. Health - related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index. *Int J Clin Oncol*. 2020;25(12):2090-2098. <https://doi.org/10.1007/s10147-020-01770-2>
64. Tyson MD, Barocas DA. Quality of Life After Radical Cystectomy. *Urol Clin North Am*. 2018;45(2):249-256.
65. Ripping TM, Kiemeny LA, Hoogstraten LMC Van, Witjes JA, Aben KKH. Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). Published online 2020:1-7.
66. Jung A, Nielsen ME, Crandell JL, Mayer DK. Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study Ahrang. 2021;125(1):38-48.
67. Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. *Eur Urol Focus*. 2020;6(4):642-649. <https://doi.org/10.1016/j.euf.2019.10.016>
68. Matsumoto Y, Samma S, Fukui S, Nakai Y, Kagebayashi Y, Torimoto K. External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer. *Indian J Urol*. 2015;31(1):52-56.

